Evaluation of steroid hormones and their receptors in development and progression of renal cell carcinoma

Main Article Content

Nigel C Bennett
Retnagowri Rajandram
Keng Lim Ng
Glenda C Gobe

Keywords

renal cell carcinoma, steroid hormones, retinoids, androgen receptor, kidney cancer

Abstract

Steroid hormones and their receptors have important roles in normal kidney biology, and alterations in their expression and function help explain the differences in development of kidney diseases, such as nephrotic syndrome and chronic kidney disease. The distinct gender difference in incidence of renal cell carcinoma (RCC), with males having almost twice the incidence as females globally, also suggests a role for sex hormones or their receptors in RCC development and progression. There was a peak in interest in evaluating the roles of androgen and estrogen receptors in RCC pathogenesis in the late 20th century, with some positive outcomes for RCC therapy that targeted estrogen receptors, especially for metastatic disease. Since that time, however, there have been few studies that look at use of steroid hormone modulators for RCC, especially in the light of new therapies such as the tyrosine kinase inhibitors and new immune therapies, which are having some success for treatment of metastatic RCC. This review summarises past and current literature and attempts to stimulate renewed interest in research into the steroid hormones and their receptors, which might be used to effect, for example, in combination with the other newer targeted therapies for RCC.

Abstract 3892 | PDF Downloads 1057 HTML Downloads 3422

References

1. Kidney Cancer Statistics. Cancer Australia. http://canceraustralia.gov.au/affected-cancer/cancer-types/kidney-cancer/kidney-cancer-statistics. Accessed May 2014.

2. Ng KL, Rajandram R, Morais C, Yap NY, Samaratunga H, Gobe GC, Wood ST. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? J Clin Pathol 2014; 67(2):97-104. doi: 10.1136/jclinpath-2013-201895.

3. Billia M, Volpe A, Terrone C. The current TNM staging system of renal cell carcinoma: are further improvements needed? Arch Esp Urol 2011; 64(10):929-937.

4. Mattei J, da Silva RD, Sehrt D, Molina WR, Kim FJ. Targeted therapy in metastatic renal carcinoma. Cancer Lett 2014; 343(2):156-60. doi: 10.1016/j.canlet.2013.09.038.

5. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343(18):1305-1311.

6. Kummer S, von Gersdorff G, Kemper MJ, Oh J. The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease. Pediatr Nephrol 2012; 27(8):1213-1219. doi: 10.1007/s00467-011-1963-1.

7. Zhu G, Liang L, Li L, Dang Q, Song W, Yeh S, et al. The expression and evaluation of androgen receptor in human renal cell carcinoma. Urology 2014; 83(2):510.e19-24. doi: 10.1016/j.urology.2013.10.022.

8. Jensen BL, Stubbe J, Madsen K, Nielsen FT, Skøtt O. The renin-angiotensin system in kidney development: role of COX-2 and adrenal steroids. Acta Physiol Scand 2004; 181(4):549-559.

9. Yakirevich E, Morris DJ, Tavares R, Meitner PA, Lechpammer M, Noble L, de Rodriguez AF, Gomez-Sanchez CE, Wang LJ, Sabo E, Delellis RA, Resnick MB. Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study. Am J Surg Pathol 2008; 32(6):874-883. doi: 10.1097/PAS.0b013e31815f2362.

10. Schupp N, Queisser N, Wolf M, Kolkhof P, Bärfacker L, Schäfer S, Heidland A, Stopper H. Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists. Horm Metab Res 2010; 42(6):458-465. doi: 10.1055/s-0029-1243253.

11. Galliher-Beckley AJ, Williams JG, Cidlowski JA. Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol 2011; 31(23):4663-4675. doi: 10.1128/MCB.05866-11.

12. Yakirevich E, Matoso A, Morris DJ, Resnick MB. Steroid Receptors in Renal Cell Carcinoma. Chapter 5. In "Emerging Research and Treatments in Renal Cell Carcinoma" Ed RJ Amato, ISBN 978-953-51-0022-5, 2012 DOI: 10.5772/26993.

13. Bennett NC, Gardiner RA, Hooper JD, Johnson DW, Gobe GC. Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol 2010; 42(6):813-827. doi: 10.1016/j.biocel.2009.11.013.

14. Chang C, Lee SO, Wang RS, Yeh S, Chang TM. Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells. Biol Reprod 2013; 89(1):21. doi: 10.1095/biolreprod.113.109132.

15. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7(5):245-257. doi: 10.1038/nrurol.2010.46.

16. Brown DF, Dababo MA, Hladik CL, Eagan KP, White CL 3rd, Rushing EJ. Hormone receptor immunoreactivity in hemangioblastomas and clear cell renal cell carcinomas. Mod Pathol 1998; 11(1):55-59.

17. Loda M, Fogt F, French FS, Posner M, Cukor B, Aretz HT, Alsaigh N. Androgen receptor immunohistochemistry on paraffin-embedded tissue. Mod Pathol 1994; 7(3):388-391.

18. Klötzl G, Otto U, Becker H, Klosterhalfen H. Determination of androgen, progestin and estrogen receptors with two different assays in renal cell carcinoma. Urol Int 1987; 42(2):100-104.

19. Nakano E, Tada Y, Fujioka H, Matsuda M, Osafune M, Kotake T, Sato B, Takaha M, Sonoda T. Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy. J Urol 1984; 132(2):240-245.

20. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol 2004; 171(2 Pt 1):611-614.

21. Hemmstreet GP, Wittliff JL, Sarrif AM, Hall ML, McRae LJ, Durant JR. Comparison of steroid receptor levels in renal-cell carcinoma and autologous normal kidney. Int J Cancer 1980; 26(6):769-775.

22. Pearson J, Friedman MA, Hoffman PG. Hormone receptors in renal cell carcinoma. Their utility as predictors of esponse to endocrine therapy. Cancer Chemother Pharmacol 1981 6(2): 151-4.

23. Karr JP, Pontes JE, Schneider S, Sandberg AA, Murphy GP. Clinical aspects of steroid hormone receptors in human renal cell carcinoma. J Surg Oncol 1983; 23(2):117-124.

24. Yu CP, Ho JY, Huang YT, Cha TL, Sun GH, Yu DS, Chang FW, Chen SP, Hsu RJ. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation. PLoS One 2013; 8(2):e56667. doi: 10.1371/journal.pone.0056667.

25. Papac RJ, Keohane MF. Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen. Eur J Cancer. 1993; 29A(7):997-999.

26. Henriksson R, Nilsson S, Colleen S, Wersäll P, Helsing M, Zimmerman R, Engman K. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer 1998; 77(8):1311-1317.

27. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41(1):41-55.

28. Armstrong JL, Redfern CP, Veal GJ. 13-cis retinoic acid and isomerisation in paediatric oncology - is changing shape the key to success? Biochem Pharmacol 2005; 69(9):1299–1306.

29. Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, Dave A, Motzer RJ, Dmitrovsky E, Albino AP, Nanus DM. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 1996; 2(6):1077-1082.

30. Berg WJ, Nanus DM, Leung A, Brown KT, Hutchinson B, Mazumdar M, Xu XC, Lotan R, Reuter VE, Motzer RJ. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clin Cancer Res 1999; 5(7):1671-1675.

31. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13(8):1950-1957.

32. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18(16):2972-2980.


33. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med1995;332(21):1405-1410.